GERD in git

Reading File

Finding Sources

Reading File

Loading Image

I now have enough to give a thorough answer. Here is a comprehensive overview of GERD:

Gastroesophageal Reflux Disease (GERD)

Definition

GERD develops when the reflux of stomach contents into the esophagus causes troublesome symptoms or complications. Physiologic reflux occurs in healthy individuals; it becomes pathologic when it overwhelms or disrupts the normal defense mechanisms.

Epidemiology

Prevalence: 10–20% in the Western world, <5% in Asia
In the US, up to 44% of people report ever having GERD symptoms; ~30% had symptoms in the prior week
Higher prevalence in North America > Europe, and northern > southern Europe
Risk factors: obesity (especially central), increasing age, positive family history
Genetic contribution: more common in monozygotic than dizygotic twins

Pathophysiology

Normal defense has three layers:

Antireflux barrier at the gastroesophageal junction — lower esophageal sphincter (LES), crural diaphragm, phrenoesophageal ligament, and angle of His
Esophageal clearance — peristalsis clears volume; weakly alkaline saliva neutralizes residual acid
Epithelial defense — pre-epithelial (bicarbonate/unstirred water layer), epithelial (tight junctions, ion transporters), and postepithelial (blood supply)

Mechanisms of failure:

Transient LES relaxations (tLESRs) — the primary mechanism; vagally mediated, triggered by gastric distention
Low resting LES pressure — allows reflux when intra-abdominal pressure rises
Hiatal hernia — spatially separates the LES from the crural diaphragm, acts as a reservoir, reduces LES pressure
Obesity — increased intra-abdominal fat raises intragastric pressure, increases tLESRs frequency, and predisposes to hiatal hernia
Acid pocket — unbuffered acid in the gastric cardia, displaced into a hiatal hernia, is the source of postprandial acid reflux
Impaired peristalsis — contractions <20 mmHg are ineffective for clearance; worsens with esophagitis severity
Reduced saliva — smoking, Sjögren syndrome impair neutralization

Damage occurs when acid and acidified pepsin breach intercellular junctions → dilate intercellular spaces → trigger chemokine release → attract inflammatory cells.

Montreal Classification

Esophageal syndromes:

Symptomatic: typical reflux syndrome, reflux chest pain syndrome
With esophageal injury: esophagitis, stricture, Barrett esophagus, esophageal adenocarcinoma

Extraesophageal syndromes:

Established associations: cough, laryngitis, asthma, dental erosions
Proposed associations: pharyngitis, sinusitis, idiopathic pulmonary fibrosis, recurrent otitis media

Clinical Manifestations

Category	Symptoms
Classic (esophageal)	Heartburn, acid regurgitation
Atypical (esophageal)	Chest pain, dysphagia, odynophagia
Extraesophageal	Chronic cough, laryngitis, asthma, dental erosions

Extraesophageal symptoms are more reliably attributed to GERD when they are accompanied by classic symptoms and confirmed by objective testing.

Complications

Erosive esophagitis — mucosal breaks visible on endoscopy; graded by Los Angeles classification (A–D)
Peptic stricture — from chronic acid exposure causing fibrosis; presents as progressive dysphagia
Barrett esophagus — intestinal metaplasia of the esophageal mucosa (specialized columnar epithelium replacing squamous); a precancerous condition
Esophageal adenocarcinoma — risk rises with BMI; relative risk 2.27–11.3× in obese patients vs. normal weight

Diagnosis

Empirical PPI trial is the initial approach for typical symptoms (heartburn/regurgitation) without alarm features.

Upper endoscopy (EGD) is indicated for:

Alarm symptoms: dysphagia, odynophagia, weight loss, GI bleeding, anemia
Failure of PPI therapy
Screening for Barrett esophagus in high-risk patients (chronic GERD >5 years + risk factors)

Ambulatory pH or pH-impedance monitoring:

Gold standard for documenting abnormal esophageal acid exposure
Useful when diagnosis is uncertain or symptoms persist despite PPI

Esophageal manometry: evaluates LES pressure and peristaltic function; required before anti-reflux surgery.

Management

Lifestyle modifications

Weight loss (most evidence-based lifestyle intervention)
Elevate head of bed
Avoid trigger foods (fatty/spicy foods, chocolate, caffeine, alcohol, mint)
Avoid meals within 2–3 hours of recumbency
Smoking cessation

Pharmacologic therapy

Drug class	Role
Proton pump inhibitors (PPIs)	First-line; most effective acid suppression (omeprazole, lansoprazole, esomeprazole, etc.)
H₂ receptor antagonists (H₂RAs)	Second-line or as-needed; less potent than PPIs
Antacids	Symptomatic relief for mild/infrequent symptoms
Alginates	Form a raft over gastric contents; useful for postprandial reflux
Baclofen	GABA-B agonist; reduces tLESRs; used in refractory cases

PPIs are taken 30–60 minutes before a meal for maximal efficacy.

Surgical / endoscopic therapy

Laparoscopic Nissen fundoplication — wrap of gastric fundus around the LES; indicated for patients intolerant of or non-responsive to antisecretory therapy (especially those with documented reflux and predominant regurgitation)
LINX device — magnetic sphincter augmentation
Endoscopic therapies (e.g., transoral incisionless fundoplication [TIF]) for selected patients

Barrett Esophagus & Surveillance

Barrett esophagus carries a ~0.5%/year risk of progression to adenocarcinoma. Surveillance endoscopy intervals depend on degree of dysplasia:

No dysplasia: every 3–5 years
Low-grade dysplasia: every 6–12 months or endoscopic eradication therapy
High-grade dysplasia: endoscopic eradication therapy (endoscopic mucosal resection + radiofrequency ablation)

— Goldman-Cecil Medicine, pp. 1429–1431 | Sleisenger and Fordtran's Gastrointestinal and Liver Disease

This is a shared conversation. Sign in to Orris to start your own chat.